Zobrazeno 1 - 7
of 7
pro vyhledávání: '"ZHEYAO HU"'
Autor:
Zheyao Hu, Jordi Marti
Publikováno v:
Membranes, Vol 12, Iss 3, p 331 (2022)
The use of drugs derived from benzothiadiazine, a bicyclic heterocyclic benzene derivative, has become a widespread treatment for diseases such as hypertension, low blood sugar or the human immunodeficiency virus, among others. In this work we have i
Externí odkaz:
https://doaj.org/article/0e869f870d1d4149aa5b13a6315d93dc
Autor:
Zheyao Hu, Jordi Marti
The NRAS-mutant subset of melanoma represents the most aggressive and the deadliest types associated with poorer overall survival. Unfortunately, for more than 40 years, no therapeutic agent directly targeting NRAS mutations have been clinically appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04da9832069350dd779a1ece8e1ae040
https://doi.org/10.1101/2023.05.25.542304
https://doi.org/10.1101/2023.05.25.542304
One of the most common drivers in human cancer is KRAS4B. In recent years, the promising KRAS targeted drug development has attracted significant new research interest and reignited the field of RAS therapeutics. To signal, oncogenic KRAS4B not only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3024e53bd6e115210d28cf5fda58aa1b
https://doi.org/10.1101/2023.04.05.535682
https://doi.org/10.1101/2023.04.05.535682
Autor:
Jordi Marti, ZHEYAO HU
Publikováno v:
International Journal of Molecular Sciences
Volume 23
Issue 22
Pages: 13865
Volume 23
Issue 22
Pages: 13865
KRAS-G12D mutations are the one of most frequent oncogenic drivers in human cancers. Unfortunately, no therapeutic agent directly targeting KRAS-G12D has been clinically approved yet, with such mutated species remaining undrugged. Notably, cofactor M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df110f965e62535c6aa177862bd8de6
Autor:
Jordi Marti, ZHEYAO HU
Activated KRAS-G12D mutations are the one of most frequent oncogenic drivers in human cancers. Unfortunately, no therapeutic agent directly targeting KRAS-G12D has been clinically approved yet, with such mutated species remaining undrugged. Notably,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::841746dc027e9739e01eadeb23231ff6
https://doi.org/10.1101/2022.07.01.498403
https://doi.org/10.1101/2022.07.01.498403
Autor:
Zheyao Hu, Jordi Marti
The use of drugs derived from benzothiadiazine, a bicyclic heterocyclic benzene derivative, has become a widespread treatment for diseases such as hypertension, low blood sugar or the human immunodeficiency virus, among others. In this work we have i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da2f505e89227ce156f53d8e655ba976
https://doi.org/10.1101/2022.02.14.480348
https://doi.org/10.1101/2022.02.14.480348
Publikováno v:
UPCommons. Portal del coneixement obert de la UPC
Universitat Politècnica de Catalunya (UPC)
Universitat Politècnica de Catalunya (UPC)
The use of drugs derived from benzothiadiazine, which is a bicyclic heterocyclic benzene derivative, has become a widespread treatment for diseases such as hypertension (treated with diuretics such as bendroflumethiazide or chlorothiazide), low blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b7948d07a8e757119efe86f1a88916
https://doi.org/10.1101/2021.08.12.456125
https://doi.org/10.1101/2021.08.12.456125